Member Info for Surprised2

Akk2, are you by an chance a second cousin of Purpleacky, the prophetic poster on this board, the bone of rampers’ lives, the nemesis of Freddieboy, last seen riding his horse on Salcombe sands. In any event if you’re it’s pleasing to note your continuing interest and your intuitive use of AI to help foresee the future of a business, which like a mythical God may once again try to exert a seiren call. Welcome back!

Why did Rene fail? Clearly its clinical trials failed, which is an understood risk, and it ran out of cash, which is also not surprising given the cost of developing a novel therapy far exceeds anything raised, but towards the end Rene seemed to have stumbled upon a unique even if unproven delivery mechanism? Yet Fosun seems to see little value, unless of course it’s licence deal allows free exploitation; Big Pharma, which has multi-billion dollar R&D budgets, equally seems unprepared to spend dimes buying Rene’s IPR. So were Rene so inept they were unable to convince others of concept or worth? Was the technology as good as we may have been led to believe? Or were we as shareholders sold a myth, while vested and perhaps incompetent interests drew down eye-watering salaries? I’ve no clue, but do understand that if the administrators suck a million bucks out of Fosun, that’s worth two cents a share ( less tax and fees of course😀). Nonetheless I enjoyed the banter and ride, even if an expensive one. The reality, we’re simply a statistic that makes up the 90+% of developments that fail. But it was always so; a punt that is now water under the Williamsburg bridge. Having said that I’m still expecting a cheque to cover a slab of Bud for some far off weekend. Have a good summer.

Over many years ‘optimists’, often implying they had deep insight or an inside track to the board room have for what ever reason portrayed an erroneous picture. Hopefully not too many took notice of their posts. But like all long term retail stockholders I take no pleasure in the fact that at every turn they got it wrong! C’est la vie.

Nothing personal Sajy.

As a LT stock holder, I’ve watched the stock price consistently fall, I’ve also noticed that most posters were, what I would call optimists; less polite individuals may call it ramping.

Rarely has there been a dissenting voice on this board, such that any new reader may get a distorted view of prospects and may be unduly influenced as a result to buy.

I take no pleasure in my contra/balancing views having been in the main right as I too will lose my shirt! I appreciate it may be unwelcome and will leave it at that; particularly as we can’t get much lower. Your filter will therefore be unnecessary.

Sajy, are you suggesting that Mr Ross and his board are hiding data that may affect the share price?

My limited understanding of UK law is that to raise funds, Rene must in return meet a number of transparency obligations: particularly making public significant information liable to impact the share price. But of course you may have an inside track to Mr Ross’ office.

👍

Thanks for the update LW and for keeping us in the loop.

Welcome back Fred. There’s been successor optimists but none with your dispositional level, altho with similar levels of prophetic skills. Since you left we’ve also lost your nemesis, Purpleachy, so will your return result in Purps resurrection too?

I’m sure the optimists will give you a heads up, and Purp, if he/she is around will no doubt provide appropriate checks and balances.

Your return will also no doubt once again raise the question, has Fred and Mr Woodford ever been seen in the same room together 😀Anyway good to hear from you. Good luck if you ultimately invest. There’s a lot of us with fingers and everything else crossed.

LW did you get a response to your email about the conference ‘no-show’? I was wondering whether Mr Ross had run out of petty-cash for the airfare or he didn’t want to be embarrassed by questions on going belly-up, or conversely whether there’s a bailout in play?

That’s what normally happens, although Mr Ross failed to get one away late last year. In recent times, retail stockholders have been offered rights issue crumbs; although thank goodness for that as my losses would be even greater!

As some stock up on Bud for the weekend by selling small Rene tranches, others, as we await Mr Ross’ response to LW’s email, may be conjugating variables of what the no-show could mean? But having ruminated on potential conspiracy theories, it’s probably as simple as we couldn’t afford the airline ticket!

Mr Ross, under the corporate risk of going ‘belly-up’ suggests in the Annual Report a mitigation that the Board places considerable emphasis on communication with stockholders. Given there’s still buyers out there, relying on goodness knows what, I’m not sure we should give him or his board any benefit of the doubt.

For those with an open line to Mr Ross, what’s the score on the conference non-attendance, which Grizzly has highlighted?

I agree with you LW, that we’re shooting in the dark and whether it’s twenty or ten cents is not going to make a tangible difference to many of us. Personally I’m not sure what success can look like pre-clinical with a six months timeline so I’m not bought into the rabbits and hats argument but on the other hand if Mr Ross creates an auction then the acquisition premium no longer applies. Let’s therefore hope that more than one bidder likes it …….. actually let’s hope someone likes it.

Historical purchase premium on acquisitions are in the range of 10-50% over market trading value. Let’s be optimistic and say trading value is ten cents and purchase premium is 40% ie the acquirer would pay 14 pennies. You right LW I certainly wouldn’t wash my face but hopefully others will. C’est la vie.

Looking at yesterday’s sale data, someone clearly needed five bucks to buy some Bud! But to Steve’s point about April being when we get put out of our misery, does anyone have a more exact date? Clearly the closer to the edge and the higher the desperation, the weaker Mr Ross’s hand. Given there’s only the janitor left has it any value as a going concern? Potential buyers who know and who work with the technology under agreement may think they’ll get a better deal on assets from an appointed administrator. But who knows?

Wink, buying penny stocks is much more akin to playing the lotto or spinning the roulette wheel than it is to investing. Whilst on this board, as there is in Vegas there’s fancy strategies posted the house aka the executive in this case, who’ve been paid for the ride, always wins. Nonetheless like rolling the ball or playing the lotto we hope to be lucky, but I’m not quite sure thats investing.

Someone bought 95 for ten bucks. Was that the kid’s allowance LW?

About 90% plus of biotech start-ups fail during clinical trials so there’s little that’s unusual about Reneuron. But yes poor leadership and poor cash management can and possibly has contributed to failure but equally good science can and does fail. Of course many of us, me included, hoped we and Reneuron would be on the right side of that curve where rewards would be eye-watering, however when I joined the ride too many years ago to remember, I knew that probability suggested I’d end up 100% down! Nonetheless it’s good to hear that some think even now there’s a British knight in shining armour out there. If one should happen to ride in, the question I suppose is, by how much will we then still be down? But fingers crossed as they say.

Once ‘ topping up’ was a frequently used term on this board, only to be replaced by ‘averaging down’. As Sajy implies, if there’s sufficient rebound it enhances gains, if there isn’t, averaging down only magnifies losses. Hopefully, although not guaranteed, it’s the former.